Eugia Pharma Receives USFDA Approval for Tirofiban Hydrochloride Injection, 5 mg/100 mL (50 mcg/mL) and 12.5 mg/250 mL (50 mcg/mL) [Single-Dose Flexible Container]

Eugia US is pleased to announce that the company has received approval from the US Food & Drug Administration (USFDA) to manufacture and market Tirofiban Hydrochloride Injection, 5 mg/100 mL (50 mcg/mL) and 12.5 mg/250 mL (50 mcg/mL) [Single-Dose Flexible Container]

Indications for this product include:

• Indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Refer to package insert for full prescribing information.